Table 3.

Univariable Cox proportional hazard analysis of factors related to loss of clinical benefit after TNFi discontinuation (n=325) while in LDA

Characteristic at discontinuation	Univariable HR (95% CI)	p Value
Age (<53 years (ref))	0.74 (0.54 to 1.04)	0.086
Gender (male (ref))	1.02 (0.74 to 1.42)	0.879
Smoker (never (reference))
Former	1 (0.67 to 1.48)
Current	1.78 (1.167 to 2.65)	0.027
BMI (overweight vs normal (ref))	0.85 (0.57 to 1.27)	0.428
Duration of PsA (>1 vs ≤1 year (ref))	0.83 (0.44 to 1.58)	0.575
CDAI (<3.2 (ref) vs ≥3.2)	1.43 (1.03 to 2.00)	0.032
TJC (0 (ref) vs >0)	1.32 (0.95 to 1.85)	0.095
SJC (0 (ref) vs >0)	0.83 (0.55 to 1.24)	0.367
Patient global assessment (<5 (ref) vs ≥5 ref)	1.70 (1.16 to 2.51)	0.007
Physician global assessment (<15 (ref) vs ≥15)	1.13 (8.82 to 1.58)	0.454
mHAQ (0 (ref) vs >0 ref)	0.85 (0.61 to 1.18)	0.338
mDAS (moderate vs low)	1.65 (1.09 to 2.49)	0.012

Factors that were significant at the 20% level (p value <0.20) were further evaluated in a multivariable analysis model, although no new differences arose.

BMI, body mass index; CDAI, clinical disease activity index; LDA, low disease activity; mDAS, modified disease activity score; mHAQ, modified health assessment questionnaire; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNFi, tumour necrosis factor inhibitor.